The equity/research analysts at the investment and securities firms listed below currently write research reports on Mereo BioPharma Group plc.
This list is subject to change and any estimates, forecasts or opinions are made by the analysts alone and do not represent the estimates, forecasts or opinions of Mereo or its board or management. Investors may wish to contact the analysts at RBC Capital Markets and Cantor Fitzgerald Europe directly in order to obtain a copy of their research report. There is no obligation upon the analysts to provide any report, and any reports issued may have become out of date after publication and should be read accordingly.
|Nick Keher||RBC Capital Markets||+44 (0) 20 7429 firstname.lastname@example.org|
|Brian White||Cantor Fitzgerald Europe||+44 (0) 20 7786 email@example.com|
|Mick Cooper||Trinity Delta||+44 (0) 20 3637 firstname.lastname@example.org||"Raring to go in rare diseases"
(PDF, 24 Sep 2018)
Never miss an update from Mereo. Sign up for and select the type of alerts you would like to receive by email.Register for Email Alerts
Share Price Information
Mereo is a specialty biopharma company developing innovative medicines for patients. Find out about our share price and latest trades.View Share Price